<SEC-DOCUMENT>0001144204-14-035122.txt : 20140623
<SEC-HEADER>0001144204-14-035122.hdr.sgml : 20140623
<ACCEPTANCE-DATETIME>20140602173415
ACCESSION NUMBER:		0001144204-14-035122
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140602
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140603
DATE AS OF CHANGE:		20140602

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEDIFAST INC
		CENTRAL INDEX KEY:			0000910329
		STANDARD INDUSTRIAL CLASSIFICATION:	MISCELLANEOUS FOOD PREPARATIONS & KINDRED PRODUCTS [2090]
		IRS NUMBER:				133714405
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31573
		FILM NUMBER:		14885254

	BUSINESS ADDRESS:	
		STREET 1:		11445 CRONHILL DRIVE
		CITY:			OWINGS MILLS
		STATE:			MD
		ZIP:			21117
		BUSINESS PHONE:		7327640619

	MAIL ADDRESS:	
		STREET 1:		11445 CRONHILL DRIVE
		CITY:			OWINGS MILLS
		STATE:			MD
		ZIP:			21117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEALTHRITE INC
		DATE OF NAME CHANGE:	19951120

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XX
		DATE OF NAME CHANGE:	19950619

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	00
		DATE OF NAME CHANGE:	19950619
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v380358_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM&nbsp;8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B><BR>
<B>Pursuant to Section 13 or 15(d)</B><BR>
<B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):<B>
June 2, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>MEDIFAST, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Delaware</U></B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>001-31573</U></B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>13-3714405</U></B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Commission file number)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer </FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">of incorporation)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>3600 Crondall Lane, Owings Mills,
Maryland, 21117</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of Principal Executive Offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B><U>(410)-581-8042</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>N/A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former Name or Former
Address, if Changed Since Last Report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD>Written communications pursuant to Rule&nbsp;425 under
the Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD>Soliciting material pursuant to Rule&nbsp;14a-12 under
the Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under
the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under
the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 8.01.</B></FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>Other Events.</B></FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 2, 2014, Medifast, Inc. issued
a press release announcing that it has entered into an agreement to sell an additional 12 Medifast Weight Control Centers located
in Northern Virginia and Southern Maryland owned by its subsidiary, Jason Properties, Inc., to TRANSFORMU, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A copy of the Press Release is filed as
Exhibit 99.1 attached hereto and is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 9.01.</B></FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>Financial Statements and
Exhibits.</B></FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD><I>Exhibits.</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">99.1</FONT></TD><TD><FONT STYLE="font-size: 10pt">Press release dated June
2, 2014</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Signature</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">MEDIFAST,&nbsp;INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Jason L. Groves, Esq.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jason L. Groves, Esq.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Executive Vice President and General Counsel</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Dated: June 2, 2014</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B><U>Exhibit No.</U></B></TD><TD><B><U>Description</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left">99.1</TD><TD>Press Release dated June 2, 2014</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v380358_ex99-1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">Exhibit 99.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><img src="medlogo.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Medifast Agrees to Sell an Additional
12 Weight Control Centers in Washington, D.C. Market to Strategic Partner, TRANSFORMU</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Sale of Centers is Part of Medifast&rsquo;s
Ongoing Effort to Transition the Corporate Centers to Franchise Ownership</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>OWINGS MILLS, Md., June 2, 2014 </B>&ndash;
Medifast, Inc. (NYSE: MED), a leading United States manufacturer and provider of clinically proven, portion-controlled weight-loss
products and programs, announced today that a subsidiary of Medifast has entered into an agreement to sell an additional 12 Medifast
Weight Control Centers located in Northern Virginia and Southern Maryland to TRANSFORMU, a South Carolina-based LLC. The Centers
will be operated as Medifast Weight Control Centers by TRANSFORMU under franchise agreements with another Medifast subsidiary.
The sale is subject to customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This deal advances Medifast&rsquo;s previously
announced plan to transition their corporate Weight Control Centers to the franchise model. Under Medifast&rsquo;s franchise model
and through its Weight Control Centers, TRANSFORMU will help members define specific needs, maximize plan effectiveness and enable
members to achieve lasting results through tailored weight loss and weight management plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;This sale is
another critical milestone in our strategic plan to transition to a franchise model,&rdquo;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">
</FONT>said Mike MacDonald, Chairman and Chief Executive Officer of Medifast. &ldquo;D.C. is a major market for us and TRANSFORMU
is well respected in the weight loss center business. This demonstrates their tremendous confidence in our brand and in our program.
We look forward to working with TRANSFORMU to support their efforts.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The senior management team of TRANSFORMU
brings tremendous experience in the weight loss center business. &ldquo;We are excited to enter the D.C. market under the banner
of a premier brand like Medifast,&rdquo; said Ron Fields, Chief Executive Officer of TRANSFORMU. &ldquo;Acquiring the Medifast
Weight Control Centers will allow us to fulfill our mission and passion to make a difference in the lives of individuals and the
greater community. We look forward to guiding clients through their weight loss journeys and supporting them in reaching their
goals.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>MED-G</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Medifast:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Medifast<FONT STYLE="background-color: white">&nbsp;(NYSE:
MED) is the leading easy-to-use, clinically proven, portion-controlled weight-loss program. The company sells its products and
programs via four unique distribution channels: 1) the Web and national call centers, 2) the Take Shape For Life personal coaching
division, 3) Medifast Weight Control Centers, and 4) a national network of physicians.&nbsp;</FONT>Medifast<FONT STYLE="background-color: white">&nbsp;was
founded in 1980 and is located in&nbsp;Owings Mills, Maryland. For more information, log onto&nbsp;www.MedifastNow.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><img src="medlogo.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About TRANSFORMU LLC:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TRANSFORMU is a South Carolina-based LLC organized for the
purposes of purchasing the assets of Medifast Weight Control Centers and acquiring franchise rights from certain
Medifast&rsquo;s subsidiaries, by James S. Smith, Ron M. Fields, Jr. and Norma Hubble. The organization will acquire
Medifast franchise rights for the D.C. market area.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-looking Statements:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Forward-looking statements in this press release regarding our
expectations, plans, anticipated benefits related to the sale, the closing of the sale, and all other statements that are not historical
facts, are made under the safe harbor provisions of the private securities litigation reform act of 1995. These statements are
based on assumptions believed by Medifast to be reasonable and speak only as of the state on which such statements are made. We
undertake no obligation to update such statements to reflect events or circumstances arising after such date, and we caution investors
not to place undue reliance on any such forward-looking statements. Forward-looking statements involve risks and uncertainties
that could cause actual results to differ materially from those described in the statements based on a number of factors, including
but not limited to the following: delays associated with closing the sale; anticipated benefits of the sale; effectiveness of our
management strategies and decisions; and other risk factors described from time to time in the Medifast&rsquo;s Form 10-K, (including
all amendments to that report) filed with the U.S. Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>medlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 medlogo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"``T`.@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#[4_;._;8_
M;!_8CU&WE\2?\*<U70=1E9;+5=%\`>)=4B'S-L2<6\S^3*5&[:25]&.*^>/^
M(A7XT\[]7^%H4=3'\+?%CN/]T-(H)]`2!GJ1UK]J;VQCU&TFMYXUFAN$,<D;
M#*NI&"".X(XK\V/V^O\`@AW<:AHFI>*/@;JOCZ7Q'/,TS>%[SXF:EIFF$-_S
M[/\`O/+(8Y\MF"$<`IQ7UN49AEM1JEC*23[I)+YW6GY>AX6-PF*C[]"HVNU]
M?^"?)EK_`,'&7Q;\$>-;.YUGQEH]_;F02KI6K_#*XT+3M20$!H5NQ>2W$!Z@
M2M"Z*2-P(!KY'_9W_;?UGX7_`/!5/6OCK)XAUK5YX[S4-7EAOM0:!M2BN(W6
M*PNIN8T@B,D88C<FVW'E*S&-3H:M^R?H'CSQ7X^T>Z\,?M+_`!K\6?#J]?1O
M$/B3P[>VMQ%8W4+%)%CL9XIKN2V5E=5D>12P4'"%L#S_`,1_\$Z=;T#XJ:WH
M=EI_Q.UVQTGPYI/B:33]/\&RGQ#'%J#*(;>YLO,(@D0L=SEF7Y00/F`'Z9@\
M)E5*,X)*+G&ST2NG;M:VZW2>I\IB:^-G*,KW2=UKL_Z['WWI'_!RM\2;;5I[
MZ;QI\'KNR,CJT%QX"U^VTV`YX6.\CF>5NHYDA4D=@376:%_P<U>+[BTDEEG^
M`^HJK<26EEXIC1..0?\`0GR>_4?2OAGX0_LQ^./`7[0&E?#CP-I?QT\"_$'Q
M/82:K:^%-9U2WTN7Q)##&[M&6A`^R3;$E,;7,3(=O.T$$_LS^PG_`,$?G^%U
M[X?\<?%#QE\2M>\6VD8F_P"$9NO&TNI:%ITN=REO+AMQ<R+WWJ8\YP&`!KYG
M.L/D>"BI2IWNKI)I-_<K6\[V^9ZN"J9E7ERQG:V[W7X_D6OV$/VS_P!I#]MV
M]T7Q1;^&?A%H_P`+6NPFH:E)!KT.H7T0&2;&.Z@@5_[OF'*`Y^]@BON3-?!7
M_!8+_@K5X]_X)5ZOX6OX?A;H/C3P5XL+VEIJ)U^6RN;6[C4.\$L0MW4!D.Y&
M5CG:X(&!GCO^"2/_``<"#_@I1^TE?_#76OAW:^![_P#L>75=-N;?6C?I=F%T
M$L+*T,95MC[P03PC<5\?B<GQ>(PSS'#T%&BD]FG9+OK=M==%Z'NTL?1I55A*
ME1NH^Z?X=#])LT9S[T$X!)[5^6/_``4Q_P"#D8_L)?M>:]\+/#OPUT_QLOAB
MWMAJ&HSZ\UGMNI8Q*T*HL$G"(Z`DMG<2,<5YF797BL?5='"0YI)7W2T^=EU.
MS&8VCA8>TKNRV/U.SCK1G-?`_P#P2"_X*U?$?_@J?KOB#46^%'A_P9X$\+.+
M2^U;_A(Y;NZGNW3>D$$/V9`V%PSLS@*&7&XG`^^%&*RQV"K8.L\/B%:2W5T[
M?<V7AL3"O356GJGMI;\PHHHKD-PHHK(\;_$'0?AGH3ZIXDUS2/#^F1NL;7FI
M7D=I;JS'"J7D(4$G@#/--)MV0-VU9KT9K@O!/[4_PR^)?C,>'/#GQ$\$>(/$
M#0M<C3M,URVN[HQ+C<_EQN6VC(R<8&17RC_P4F_X+X?#'_@F[\9K/X?:MX<\
M5^,?%#646H7\.E"&*+3H92?+#22LH:1@I8*H(`QDC.*[<+EN*Q-98>A3;DU>
MUNG?7H<];%T:4/:5))1[GW717#?LT_M">'/VKO@/X7^(WA&>XN/#GBZQ6_LF
MGB\J9%)*LDB\[71U96&2,J<$CFNPU;6+30--N+V_NK>RL[1#+///(L<4*`9+
M,S8"@#N37).$H2<)*S3M;S-U-2BI)Z,LT5\T>+_^"R7[+7@7Q`^EZC\=/AZ+
MR-_+<6^HBZCC//WGB#(HX/)(&>.M>X?!WXU>$OV@_A_9>*_!'B+2O%7AO42X
MMM1TVX6>WF*,4<!AQE6!4CJ""#R*VK82O2BIU8.*?5II?B9PKTYNT))OR9T]
M%%%<QJ%%%%`!11N[5GZ1XNTO7]4U&QL=2L;V]T>58+^""=9)+*1D#JDJ@DHQ
M0JVUL'#`]"*=F#9H4444@"ANG>BBA@?CI_P<B?L=_#[X7ZAX"^+'AG37^''C
MGQ]XQMM$\0^/[&^N[2TTF%XV)NKJ*W^^YV#+KAR(S]YB,?*NH?L;Z)I/[57Q
M7TIOVVK_`$NQT;X>Z7K=K\0I?$!>+Q*9&*_896BN#*\<;(-L:/)(HVG:Q(!_
M<S_@HO\`"76OCE^PQ\5?"OANST:_\1ZSX;O(=+AU6"*6U:Y\IC&2)?D5@1\K
MMPC;6R,9K^8C0_"_PH^)VKV7A+P1X*\81>.M?T30M$\.MJ&IV_V1/%)O/+OK
MJXD=O*>RE!"HN`.!TP2?U;A+%5<5@7!S:]GHW:,M&TTWS;)6:2U6[M='QV=4
MH4:ZERKWM=VM5=/;=N]S]I?^#:+]E+P%%^R#I/QKD\"RVGQ/\03WVG7/B?4K
MJ>\N-6MDG*BXMO./[F.0`*=@!8QG)((`_3L#`Q6-\.?#S>$O`&B:4\%A:R:;
M806SPV,*PVL3)&JE8D4!50$'"@``8X%;-?G.:XZ6,Q53$2^TW97O9=$GV1]1
MA,.J-&--=$?B_P#\';GB23Q;JO[/GP[TU?M&LZMJ.H7L4`(!=W-M:PC/;<\C
MC\/:OS:_X)Y_$C5_^"??_!5'P%=^)DDT6^\'>+CX<\20,RG[-')(]E=JQ!P0
MHD8Y!P=@(K]$/^"F[?\`#4__``<O?`GX?HOVNS\%?V.;J)3N"[))M4FR.W[M
M8\Y]O:OC_P#X./?V?&^!G_!4WQC>V\#6VG_$*RM?%%HZC`,DB>3<$8[^?!(Q
M]W![U^M\-U(+!T<GJ+^+2E)_]O2?Z-_<?#YO&7UB>/C]B:C]R/Z/?VD_COHW
M[,7P`\8_$/Q!($TCP=I-QJLXW8,WEH66-?\`:=MJ+ZEA7\D7QWT[Q_\`%BVN
MOCIXMLIFT_XH^)M3$>IO(I6[OHRDUQ&JYW;(Q.BAL;>"H.5('Z;?\%7?^"E&
MH_M<?\$L/V9OAMX7E>_\:?&V&TDUVVA8M)+)93+9^0P_Z;:@NX`]1!Z&C_@X
M;_9-TG]C3_@F]^RM\/M,.[_A#;R\L)Y4X6[N);59;J<^I><,WL&Q7F<(TO[*
MJ4X55^\KSE'TC!.[^<OP.S/)_782E!^[3BGZN5OT/I__`(-.#:C_`()S^*A"
MDJW(\>WHN68@J[?8[+;M]@NT<]\U]\_M'_M>_#+]D+PK%K7Q,\;^'_!NGW#%
M(&U"Y"2W+#J(HAF20CN$4XK\TO\`@U.^)<'A;]@+XP2WLBM9^%_%4^JS1QKF
M58SIT#L??(A./H:_(KXF_M.7?_!0/]N_3?''QD\07$&A>)O$=M'J$K,[Q:#H
MS7*[H($7)6..`D849)RW+$D\-7AIYEG6+E4DXP@[NVK=U=)'1#-UA,OH**O*
M2LK[>K/Z!=*_X.._V0-5UF*R_P"%HSVYE<H)[CP[J4<`P<;BY@P%]Z^O_A+\
M9/"OQY\!V/BCP7XATCQ3X>U%=UMJ&F727-O+CJ-RDX8="IP0>"!7Y<?\%`OB
M-\'/V\_V']2^$GP)^`?Q*\<:AIEM$G@S5M$^'\^EZ3H<\;*$D6\NEA"Q%-RM
M@-O5CGGD>>_\$<?V2?VF_P#@D99_$;XC?$W1=/T'X.P>%K_6=9T*?78KB[:[
MMH3+!/##"71)3L,3%F&5<9SM7'CU\BP4\'*M2DZ55.RA-Q;EMLDDT_EO]YWT
M\RQ$:ZA-*<&KN44[+UU:/UO^/O[57PW_`&6/#::O\1O&_AKP982Y\E]5OD@>
MX(ZB-"=\A'H@)K\\O^"JG_!8K]D[]I[]@+XM^`='^(^B>*?$6KZ'-'I-BVD7
MC"6^4AH&1WA"*PD565R0`1G-?C!>^,?B+_P5B_;NT!?%>NS:AXP^)^OV^DQ3
M2DM;Z1#-*%$<*=$AAC)(48SLR<DDG]__`-N#]BKX;?L8?\$7?C-X1\`^%M*T
MFRTSP/=J]W]G1[W4)5BYN)YB-TDK-EBQ/!.!@``>C6X?PF45\-'$SE.M.47:
M+22U75IMZ^E_(YJ>9U\="JZ*48135W=MZ>J/R9_X-=H$C_X*KZ<%101X4U7H
M`.T-?HQ_P53^!G[!/[2'[1TVI?&SXJ67@_XC>&K6.PU6#3=?%G=SPH"\<5Q$
M8Y,L%<[2@5RK`9(VX_.K_@UY^;_@JQIY]?"FJ_RAKH/^#K/0[73/^"E>AW,$
M$<5QJ7@:PFNG48,[K=7D89O4A$5?HHKZ/,\(\3Q.J4:DJ;=.]XNSZZ==#R,'
MB51R?VDHJ2YMF?NO^R?J/PI\"_L?^$+KX9ZAI%I\(M*T9)-&OA.T=FEB@/[U
MI)L'&0S,[X)))-?@]_P<3?\`!5U/VR_C?%\.OASXL_M;X1^$H%:XDTV8_8O$
M6I')>0L,":*)=J)U3=YC#.0:_8S_`((O6%OJ?_!(_P"!MO>10W%K-X3A26*9
M`\<B[GR&!X(QV-?SI:]I<7[<G_!5*ZL-)M(;>P^)7Q,-K:V]M"L<<-I+J&Q=
MJ+P%$`SQQP37A\&X&BLRQ->NG+V-W=][O5^=D]3TL_Q-3ZK2I4]/:6T7HM/0
M_;[_`((@6G[+EG^QGX<^%?A'7/A[XS\9ZUX:76O'%H(5GN[N25%^T_:0ZY$4
M1E$(5L*H``'))]MT[]N/]DS_`()R_"O0?AS%\5?A_P"&]'\)V:V5GI5KJBW]
MU;HI).^.#?)O9B22PR22>]>\?%+X&:7\0/@KXH\%V'D>&X?$NAW.A?:[&TB$
MEE%-"T.Y%(VDJK9`/&0*^9=+\;?L9?\`!'/X?V/@(:O\/?!-S9P1Q/8K&NH>
M(-4<``23I$CW$LKGG++C)^4`8`^5E6IXVM.;52;E*_*G=OS;MI:]DE%Z=4>R
MH3P].,4XJRM=JR]+7_4Z'X:?\%ROV4/BSXDM=)TGXU>%TOKV18H!J"7&G12,
MQP`)+B-$SGCENM?5HN%,0D#`H1NW`C&/7/I7\LW_``72\8?#;XD_MX7VN?#/
MPGJ_A/1=8T.TN+^VU'P]/H37MXS2[[E+69$8))&(OGV*'96/)R3^A7[5?QS^
M)B?\&MGPPUWPS>ZLMUJ.F:9H_B74+:1VN(-(5Y;=V:0?,JN8[>-VS]V1@>":
M]S,.$:<886K0FX^VDHM3M>+?FK?EV/.PN>3E.M"HD_9J]X]3[U^)'_!9C]F7
MX6^.)/#6H?%O0+_7XG:-['18+G69491EE/V2.49'<9R*Z[X(_P#!27X%_M$^
M+X?#GA/XE^'+WQ+<C,.BW<CZ=J<W&?EMKE8Y6XYX4]#Z5_.#_P`$AO\`@J'_
M`,.L?C)KGB-O`FF>-=.\2V,5A=+YPM=0L41V8&VF*L%#%OG0C#[4Y&T5^N/P
MH_X+:_L:?M[_`!3^']_XWM+SP)\0/"6JQWWAV]\36*V_V*[*M'L2_A9HQ&ZR
M,"LK(C9!(R`0\ZX/E@I-4Z52<4OC33UM_*E=*_GYBP&>K$).4XQ=_A:?YWM^
M!:_X./O^"E4O[+/[.>G>"?AO\26\-?%G7=7@>YMM(GC;4K32A%*97<X+6X9_
M)"M\KG^$XR:^<_\`@VT_X*,?"+]FK]G;XFZ7\6/B9H_ACQ)K'BW^V=^N73B7
M48Y+6%#-YC9,C;XW#9);H3UKT;_@[@T'3D_9:^%>J165B+^X\7O&UVD*>=)&
M;&<[?,`W%20IQG'`]!5G_@TH\-Z=J?[&_P`3;BYL+*XG;QKY9DE@1W*BQMB%
MR1G`+$@=LGU-=E*CA8<*.K*#]Z6MFDVT[;V>GD85*M:6=*FI+1:;VV]=S]9=
M$UNU\1Z/::A93+<6=_"EQ!*N=LL;J&5AGL00:*LJNT`<<>U%?FQ]8+1110!5
MUS1K;Q%H]WI]["MS9W\+V]Q$WW98W4JRGV()%?S"_L7_``EO-=_X*R>`OAA>
M?VE>Z3H_CJ#3Y-`DOLZ=!9:;J%[.D"78D/G16PC,D>,F5S(F`02?ZA">*_#/
M]B/]G]M,_P"#H+X@Z5/I^B"'PC?:OXC6VBE7[+:03PE[=X(L?+,#?0,1_"7G
M/\0K[;A'&>QH8Q7_`.7;:]5=?J?/YW1<ZM"W\UOR_P`C]S`>M4O$7B&R\)Z#
M?:KJ=W!8Z=IEO)=W=S.X2*VAC4L\C,>`JJ"23T`JXHP!7CW[8G[%7AG]M_P+
M_P`(MXRUKQM:>&YE:.]TW0];ETR#5$)4[+GR^95!484G;R<@U\;15-SBJKM'
MJTK_`(:'NU')1;@KL_&W_@CG\7K/]N+_`(.(O'GQ7ED(M[NSUO5]&27AS;CR
M;*V&#T(MG!([<U[!_P`'=/[/IU/X:_";XJ6L)+Z+J-SX9OY`.?+N8_/@S[!X
M)1]9*^I?A?\`\&Z7[._P1\=6'BCP;+\3O"_B/2R6M-2TSQA=V]S;Y!5L,#T(
M)!!R"#@@BOHG]I[]ASP9^V'^S"_PG^($NOZWX=D%JSWAO]FIO+;NKI,9PO\`
MK"5PS;>0S>M?;U^(\)#-L/CL*Y<E.*BTU9J*33MK9Z/[SY^GE=:6"J8:M;FD
MV[WZO4_"_P#X-F/V$[S]H_\`;1C^*.KV<C^#/A!_I4,DBDQ76KR*1;Q+GJ8E
M9IVQT(BS]X5]B_\`!W7K5K;_`+*/PFT]Y`+V[\7RSPICEHX[*4.?H#)'_P!]
M"OTT_9N_9I\$_LC_``?TKP)\/=`M/#GAG2%;R;6#<S2.QR\LCL2\DC'EG<DG
MUP`*\!_:V_X(I?!S]N7XE-XI^)M]\1?$5_%O6RMV\3SQ66EQN06BMX5PD:$@
M9P,G`R3@5,N*:6(SR&95[JG#X4E=VU\[7;=W]PUD\Z672PE.SE+=GY\?\&F'
MB33_`!EX4_:&^&NH2.4UFVL+XQ!\%H)([FUF*CL>8P3[K7YN_&KX$^.?^"4'
M[=UAIGB#2G&K_#SQ!;ZUH\LZ?Z-KUI!<B2"XC)X:.14`./NL64X*D5_0'\%/
M^#?GX#_LU>.X?%'P^U#XI^#O$,,;0K?Z7XPNH96C;&Z-ARKH<#*L""0..!7T
MM^T/^QY\,OVM_!5OH'Q-\%Z'XVL+0'R#J=N'N+=B,%XYEQ)&QQR492:[UQEA
MJ&95L32BY4JR7-%JS32M=:M/KVW.;^PJM3"4Z,VE.GL]T[N^I3_9-_;3^'?[
M:?P8TSQSX%\1Z?J.F7UN)KFW:=4N]*<#YX;F+.Z*1&R"&&#C()4@GSW]H/XK
M^#/V[_A;\<_@3\/_`!-8^(?%T7@VZM-0ET]UN++3)[R&:*W@EG4E!,S(Q,8)
M*JI+8XSY3_Q#<_LDPW$\L'@37;3[1D.L'BG4HU*G^`XFR5]CFOI;]DK]ACX4
M?L+^$]0T3X4^#-.\(6&KRI<7PMY)9I;V1%*JTDDK,[$`D#)P,G&,U\C6EEU*
M3JX24W)-.*E%)+5/5J3O]R/;@L547)744FM6FW?3HK*WWL_E7_9&^)EQ^Q/^
MW1X`\4>+-)O[&X^&WBNVGUS39H62ZM5AEV7$90X(D5=Y`[D#UK^DO_@JQ\5O
M#?Q&_P"".WQD\4Z'KVE:KX=U[P3<RZ=J-O<J]O>"5`L81LX)9F"@==QQC/%=
MC^U+_P`$I?V?/VS?%0U_XB_#+0];\0!!&VJ0O-87LP`PHDEMW1I<#@;RV``!
MQ7C:_P#!N;^RLN@?V2/"?BHZ5YOG_8?^$PU/[+YG]_RO.V;O?&:^FS7B3+LR
MK8?%UE.%2FU=)*2:33LO>3WZVZGDX+*L5A(5*--QE&5[7;37X,_)?_@UY;R_
M^"K.G`D#/A350,G!/$-=5_P=?7"3?\%(?#*+(C/'X"L@X!!*$WM\0#Z<<U^L
MW[/'_!"[]G3]E7XR:'X_\">&/$&A^*?#LK2V=TGB2^<?,A1T=&D*NC*Q5E8$
M$'I5K]IG_@B)^SU^V#\:-6^('Q!\-:[KGBC61$D]R?$5["BI$@1(TC20*B*H
M^ZH`R2>I-=4N+\`\[69VER*'+:RO?_P*UCG61XG^SG@[KFYKWN[6^X\K_99^
M-:?L\_\`!MKH/C0S&*;0?A9<2V[J<$7#1RQP@>_FL@^M?DS_`,&VGP5_X6S_
M`,%6/!EW/$UQ:^!M,O\`Q#,<9"ND/V>)B?\`KK<*?J*_0#_@O;X7\&?\$W_^
M"0>D_`_X>_VKI^D^.O$\5I8Z==:E/?/%;1R&]N51I69A'YJ1#8#@&;@<UWW_
M``;=?\$PM9_8P^!VL?$CQYITVE^/?B7%"D.G7"%)]&TN,EXXY`>5EE<^8ZGE
M0L0.&#`/#XZCA<FQ>+3L\1.2A?1M>FNUW<=;#U*V/H46M*44WVO_`$D>@?\`
M!Q)^VAXW_8N_8&2^\`W=UI&O^,M<A\.G68$_>:3!)#-+(\;?P2LL6Q'ZJ6)&
M&`(_-[_@V*U#X+Z=^T/\2/&GQ7\0^'+3X@:39V]SX=NO$U]%&@1VE-Y=1RSM
MAKA2(@6SO5&8CAFK]W?VA_V<_!7[5OPFU3P/\0?#UCXF\,:P%^T65R"`&4AD
MD1E(:.16`*NA#`]#7QI\/_\`@V9_9/\``_C%=6N?"OB3Q-%'+YL>G:SKLT]B
MA[*8TV%U'I(S`]\C->1E.=8"CE%7`5E*,YO644FVM--6O2VUF=V-P&)GC88B
M#3BNCOIY_J?BO_P6^_:BT[]L'_@HOXP\9Z`;F;PFUM:Z9H%[+&R1ZI9VR&/[
M7#N`W0R3"<HPX(Y]A^V/_!+S]HCP'^S]_P`$>?V:D^(6H66FZ+XYA3PM!/?(
MK6+7-P]VT<4Y;Y5201,F6^7<R@X!R/7OVL/^"/\`^S_^VEJGAF\\=>!DGF\'
MZ6-%TG^S+V?3$M;)6W);A8&13&A+;1CY=S8ZUH:9_P`$J/@9:_LJ67P3U#P:
M?$/PTTR_?4[+2=7U*ZO/L4[[R6BE:3S(\&20@*P`,C8QFMLTXBR_&9?A\%RR
MC[-J^ST2:T=U=[/9=3/!Y7B:&*JXCF3Y_7NGJNQYE\>_^#?#]E3X_P!Q<WDG
MPZ7PCJ5VQD:\\+7LNF88]Q"I,'_D/%?SW?\`!0G]C[3OV5OVYO%_P>\$:Y<?
M$.#2K^#3].EAB62[N)YXT86;+'P\Z._E,%`RP^ZIR!_1!??\$5_!-OX4;PYX
M>^+7[1W@_P`*MM3^PM*^(EW]A2(=8D$PD=$(P,*XP!QCFNA_8S_X(Q_L^_L,
M^*D\1^#?!K7WBR(MY>OZ[>/J>H0EOO-&TGR1,><M&JL<G)P<5MDO%:RY3E.O
M.LFK1BU97[MMNW:RON1C\F^M.*C3C!WNVO\`))?C8_/W_@XE^%GB/X8?\$A?
MV9M"\0FXO-7\)WNFZ7J]RQ#A+I='EC8,PZDNC`'OBM3_`(-+/CYX7T/X'_%;
MP/J6MZ5INNP:_%KL5M=720RW%J]JD32(&(W*C0$,1]W<N<9%?JU^TA^S3X(_
M:V^$FI^!?B%X>L_$WAC5MIGM+@LI5U.Y)(W4AXY%/(=2"/7DU\5^'/\`@U^_
M90T'Q,=0N-#\:ZQ`'W#3[WQ)/]E4=US&$D*D<<N:YL/Q!@JV3SRW&<T9.3DG
M%)K5WV;7FC2KEE>&.CBZ%FDK6;MTMV9]PZ#\?_!'B?P[HVKV/B[PY<:7XCN)
M+72;H:A$L6J2I(T;)`Q($IWJ1\F<]L@BBOE+]N#_`((I^%/VM'^'-GH>NQ^`
M?#WP]TC_`(1^UTJUTM;F*&R#J5%N2ZF*154C+;U)\MB"8QDKPJ6$RV<%*>(<
M6[Z<C=M=-4[;'HSKXN,FHTDUWYK'VY1117BGHB-TKB=#_9W\#Z!\<-8^)=EX
M8TFV\>:_I\.D:AK<<(%U=VL+%HXV;IP3R0,L%0$D(H!15*<HI\KM?1^8I).U
MUL=N!CU-%%%2,****`#%%%%`!1C'XT44`%%%%`!1110`8I'X`HHH8'R/HW[-
M'A/]K;]O_P`6>/OB#8OXCO\`X(7EOH?@[3;E@VEZ49;:&[DO?((P]VTC@>8Y
M(58H]JJR[C]<(.`>]%%>AF,Y.5.+>BC&R[72;M\]?4Y,*E:3ZMO\Q:***\\Z
4PHQ110`4444`%&***`"BBB@#_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
